Disc Medicine, Inc. (NASDAQ:IRON) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Disc Medicine, Inc. (NASDAQ:IRON) have been given an average rating of “Moderate Buy” by the seven research firms that are currently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $57.29.

A number of equities research analysts have weighed in on the company. Wedbush reaffirmed an “outperform” rating and issued a $43.00 price objective (down previously from $84.00) on shares of Disc Medicine in a report on Monday, April 1st. HC Wainwright reiterated a “buy” rating and issued a $70.00 price objective on shares of Disc Medicine in a research report on Monday, April 1st. Raymond James restated an “outperform” rating and set a $40.00 target price (down from $75.00) on shares of Disc Medicine in a research report on Monday, April 1st. Stifel Nicolaus increased their price target on shares of Disc Medicine from $71.00 to $73.00 and gave the company a “buy” rating in a report on Monday, April 8th. Finally, BMO Capital Markets reduced their price objective on shares of Disc Medicine from $80.00 to $50.00 and set an “outperform” rating for the company in a research note on Tuesday, April 2nd.

Insider Buying and Selling at Disc Medicine

In other news, Director William Richard White sold 2,560 shares of the firm’s stock in a transaction that occurred on Thursday, April 11th. The shares were sold at an average price of $31.80, for a total transaction of $81,408.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 4.71% of the company’s stock.

Institutional Trading of Disc Medicine

A number of large investors have recently made changes to their positions in IRON. Strs Ohio purchased a new position in Disc Medicine in the 3rd quarter valued at about $28,000. AJOVista LLC acquired a new stake in Disc Medicine during the fourth quarter worth approximately $63,000. China Universal Asset Management Co. Ltd. acquired a new stake in Disc Medicine during the fourth quarter worth approximately $161,000. Bleakley Financial Group LLC purchased a new stake in Disc Medicine in the 4th quarter worth approximately $215,000. Finally, Simplicity Solutions LLC acquired a new position in Disc Medicine in the 4th quarter valued at $215,000. Institutional investors and hedge funds own 83.70% of the company’s stock.

Disc Medicine Price Performance

Shares of NASDAQ IRON opened at $29.79 on Monday. The stock has a fifty day moving average price of $48.02 and a 200 day moving average price of $54.10. Disc Medicine has a 1-year low of $25.60 and a 1-year high of $77.60. The company has a market cap of $719.13 million, a PE ratio of -8.31 and a beta of 0.44.

Disc Medicine (NASDAQ:IRON) last released its earnings results on Thursday, March 21st. The company reported ($0.97) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.22). Analysts anticipate that Disc Medicine will post -4.44 earnings per share for the current fiscal year.

Disc Medicine Company Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.